{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:18:41Z","timestamp":1790255921015,"version":"4.1.0"},"reference-count":46,"publisher":"Impact Journals, LLC","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2015,5,30]]},"DOI":"10.18632\/oncotarget.3761","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T06:31:59Z","timestamp":1442298719000},"page":"13119-13132","source":"Crossref","is-referenced-by-count":44,"title":["Anti-tumor activity of selective inhibitors of XPO1\/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin"],"prefix":"10.18632","volume":"6","author":[{"given":"Michelandrea","family":"De Cesare","sequence":"first","affiliation":[{"name":"Molecular Pharmacology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Cominetti","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Doldi","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Lopergolo","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Deraco","sequence":"additional","affiliation":[{"name":"Peritoneal Surface Malignancy Program, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gandellini","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Friedlander","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics Inc., Newton, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosef","family":"Landesman","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics Inc., Newton, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Kauffman","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics Inc., Newton, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Shacham","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics Inc., Newton, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Pennati","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Zaffaroni","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2015,4,18]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMra050152","article-title":"Advances in malignant mesothelioma","volume":"353","author":"Lake","year":"2005","journal-title":"N Engl J Med"},{"key":"2","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1245\/s10434-012-2845-x","article-title":"The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"20","author":"Kusamura","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"3","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ctrv.2011.10.006","article-title":"Diffuse malignant peritoneal mesothelioma\u2014an update on treatment","volume":"38","author":"Morris","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"4","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1016\/j.ejca.2013.05.027","article-title":"Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC)","volume":"49","author":"Deraco","year":"2013","journal-title":"Eur J Cancer"},{"key":"5","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1245\/s10434-008-0219-1","article-title":"Diffuse malignant peritoneal Mesothelioma: failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC)","volume":"16","author":"Deraco","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"6","first-page":"453","article-title":"Survivin is highly expressed and promotes cell survival in malignant peritoneal mesothelioma","volume":"29","author":"Daidone","year":"2007","journal-title":"Cell Oncol"},{"key":"7","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.canlet.2012.03.005","article-title":"Targeting survivin in cancer","volume":"332","author":"Altieri","year":"2013","journal-title":"Cancer Lett"},{"key":"8","doi-asserted-by":"crossref","first-page":"5999","DOI":"10.1158\/0008-5472.CAN-07-0494","article-title":"Nuclear and Cytoplasmic Survivin: Molecular Mechanism, Prognostic, and Therapeutic Potential","volume":"67","author":"Knauer","year":"2007","journal-title":"Cancer Res"},{"key":"9","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.bcp.2011.12.016","article-title":"Nuclear export of proteins and drug resistance in cancer","volume":"83","author":"Sullivan","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"10","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1006\/excr.2002.5492","article-title":"Crm1-mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein survivin","volume":"275","author":"Giaccone","year":"2002","journal-title":"Experimental Cell Research"},{"key":"11","first-page":"137","article-title":"The CRM1 nuclear export protein in normal development and disease","volume":"3","author":"Altura","year":"2012","journal-title":"Int J Biochem Mol Biol"},{"key":"12","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.exphem.2012.09.002","article-title":"Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma","volume":"41","author":"Pham","year":"2013","journal-title":"Exp Hematol"},{"key":"13","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/j.gastro.2012.10.036","article-title":"Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice","volume":"144","author":"Mohammad","year":"2013","journal-title":"Gastroenterology"},{"key":"14","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1073\/pnas.1217203110","article-title":"Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1","volume":"110","author":"Chook","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"15","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/leu.2012.219","article-title":"Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells","volume":"27","author":"Kung","year":"2013","journal-title":"Leukemia"},{"key":"16","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1182\/blood-2012-05-429506","article-title":"Selective inhibitors of nuclear export show that CRM1\/XPO1 is a target in chronic lymphocytic leukemia","volume":"120","author":"Johnson","year":"2012","journal-title":"Blood"},{"key":"17","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/blood-2012-04-423160","article-title":"Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia","volume":"120","author":"Garzon","year":"2012","journal-title":"Blood"},{"key":"18","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1182\/blood-2012-08-447581","article-title":"Prognostic impact and targeting of CRM1 in acute myeloid leukemia","volume":"121","author":"Kantarjian","year":"2013","journal-title":"Blood"},{"key":"19","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/j.juro.2012.10.018","article-title":"CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth","volume":"189","author":"Weiss","year":"2013","journal-title":"J Urol"},{"key":"20","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1158\/1535-7163.MCT-12-1171","article-title":"CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma","volume":"12","author":"Cusack","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Walker, Oaks, Santhanam, Neviani, Harb, Ferenchak, Ellis, Landesman, Eisfeld, Gabrail, Smith, Caligiuri, Hokland. Blood. 2013; 122:3034\u20133044.","DOI":"10.1182\/blood-2013-04-495374"},{"key":"22","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1158\/1535-7163.MCT-13-0416","article-title":"XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer","volume":"13","author":"Altura","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"23","doi-asserted-by":"crossref","first-page":"6102","DOI":"10.18632\/oncotarget.2174","article-title":"Selective inhibitors of nuclear export (SINE) as novel therapeutics for prostate cancer","volume":"5","author":"Kachhap","year":"2014","journal-title":"Oncotarget"},{"key":"24","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/bjc.2014.260","article-title":"KPT-330 has antitumour activity against non-small cell lung cancer","volume":"111","author":"Koeffler","year":"2014","journal-title":"Br J Cancer"},{"key":"25","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/leu.2013.115","article-title":"CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications","volume":"28","author":"Kashyap","year":"2014","journal-title":"Leukemia"},{"key":"26","doi-asserted-by":"crossref","first-page":"e102983","DOI":"10.1371\/journal.pone.0102983","article-title":"Novel Small Molecule XPO1\/CRM1 Inhibitors Induce Nuclear Accumulation of TP53, Phosphorylated MAPK and Apoptosis in Human Melanoma Cells","volume":"9","author":"Lesinski","year":"2014","journal-title":"PLoS One"},{"key":"27","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/cas.12430","article-title":"Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma","volume":"105","author":"Kimura","year":"2014","journal-title":"Cancer Sci"},{"key":"28","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00280-014-2495-8","article-title":"KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma","volume":"74","author":"Koeffler","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"29","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/leu.2014.9","article-title":"Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells","volume":"28","author":"Andritsos","year":"2014","journal-title":"Leukemia"},{"key":"30","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1038\/cddis.2010.34","article-title":"Survivin withdrawal by nuclear export failure as a physiological switch to commit cells to apoptosis","volume":"1","author":"Li","year":"2010","journal-title":"Cell Death Dis"},{"key":"31","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1242\/jcs.089110","article-title":"Protein localization in disease and therapy","volume":"124","author":"Link","year":"2011","journal-title":"J Cell Sci"},{"key":"32","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13045-014-0067-3","article-title":"SINE (selective inhibitor of nuclear export)-translational science in a new class of anti-cancer agents","volume":"7","author":"Gerecitano","year":"2014","journal-title":"J Hematol Oncol"},{"key":"33","doi-asserted-by":"crossref","first-page":"9112","DOI":"10.1073\/pnas.96.16.9112","article-title":"Leptomycin B inactivates CRM1\/exportin 1 by covalent modification at a cysteine residue in the central conserved region","volume":"96","author":"Horinouchi","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"34","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/bjc.1996.415","article-title":"Phase I trial of elactocin","volume":"74","author":"Brampton","year":"1996","journal-title":"Br J Cancer"},{"key":"35","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1002\/cncr.23354","article-title":"Expression of the nucler export protein chromosomal region maintenance\/exportin 1\/Xpol is a prognostic factor in humman ovarian cancer","volume":"112","author":"Denkert","year":"2008","journal-title":"Cancer"},{"key":"36","doi-asserted-by":"crossref","first-page":"E315","DOI":"10.25011\/cim.v32i6.10668","article-title":"Prognostic value of CRM1 in pancreas cancer","volume":"32","author":"Sun","year":"2009","journal-title":"Clin Invest Med"},{"key":"37","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1227\/01.NEU.0000348550.47441.4B","article-title":"Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis","volume":"65","author":"Cheng","year":"2009","journal-title":"Neurosurgery"},{"key":"38","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/ijc.24146","article-title":"The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation","volume":"124","author":"Leaner","year":"2009","journal-title":"Int J Cancer"},{"key":"39","first-page":"229","article-title":"The expression of CRM1 is associated with prognosis in human osteosarcoma","volume":"21","author":"Zheng","year":"2009","journal-title":"Oncol Rep"},{"key":"40","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1182\/blood-2012-08-447581","article-title":"Prognostic impact and targeting of CRM1 in acute myeloid leukemia","volume":"121","author":"Kantarjian","year":"2013","journal-title":"Blood"},{"key":"41","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/35042675","article-title":"Surfing the p53 network","volume":"408","author":"Levine","year":"2000","journal-title":"Nature"},{"key":"42","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1093\/emboj\/18.6.1660","article-title":"A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking","volume":"18","author":"Wahl","year":"1999","journal-title":"EMBO J"},{"key":"43","doi-asserted-by":"crossref","first-page":"6565","DOI":"10.1128\/MCB.10.12.6565","article-title":"Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis","volume":"10","author":"Rotter","year":"1990","journal-title":"Mol Cell Biol"},{"key":"44","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13045-014-0078-0","article-title":"Selective inhibitors of nuclear export (SINE)\u2014a novel class of anti-cancer agents","volume":"7","author":"Sekhri","year":"2014","journal-title":"J Hematol Oncol"},{"key":"45","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Talalay","year":"1984","journal-title":"Adv Enzyme Regul"},{"key":"46","first-page":"117","article-title":"In vitro pharmacodynamics of 1-b-d-arabinofuranosylcytosine: synergy of antitumor activity with cis-diamminedichloroplatinum (II)","volume":"48","author":"Hildebrand-Zanki","year":"1988","journal-title":"Cancer Res"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.3761","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T09:29:39Z","timestamp":1599557379000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.3761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,18]]},"references-count":46,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2015,5,30]]}},"alternative-id":["3761","25948791"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.3761","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,18]]}}}